Skip To Main Content
Baak MD on Muck Rack

Baak MD

As seen in: Frontiers
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Baak

Contact Baak, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Correction: Body mass index and fasting insulin predict survival and EGFR–TKI benefit in Stage IV lung adenocarcinoma

|
By Baak MD
| Frontiers
CORRECTION article Volume 16 - 2026 | doi: 10.3389/fonc.2026.1928120 CORRECTION article Article metrics View details Abstract Correction on: Guo H, Liu L and Baak JPA (2026) Body mass index and fasting insulin predict survival and EGFR-TKI benefit in Stage IV lung adenocarcinoma. Front. Oncol. 16:1742177. doi: 10.3389/fonc.2026.1742177 The reference for 5 was erroneously written as: 5. de Jager VD, Timens W, Bayle A, van den Berg A, van der Wekken AJ, Groen HJM, et al.
Open in Who Shared Issue with article?

Real-World Evidence of Baseline Soluble CD25 as a Prognostic Biomarker and Indicator of Differential EGFR–TKI Benefit in Stage IV Lung Adenocarcinoma

|
By Jan Albert, Baak MD
| Frontiers
Abstract Background Outcomes in stage IV lung adenocarcinoma (LUAD) remain heterogeneous despite established genomic and immune biomarkers. We evaluated the prognostic and predictive value of soluble interleukin-2 receptor (sCD25), a marker of systemic inflammation and immune regulation. Methods In this prospective observational real-world study (2020–2024), 133 consecutive patients with newly diagnosed stage IV LUAD, ECOG performance status 0–1, and survival ≥3 months were enrolled.
Open in Who Shared Issue with article?
See all 2 articles